In interstitial lung disease (ILD), quantitative computed tomography (qCT) is effective for prognosticating and for disease monitoring.

Pulmonary Fibrosis/Interstitial Lung Disease Program Contact Information. UAB Interstitial Lung Disease Program THT 422, 1900 University Boulevard Birmingham, AL 35294-0006 Phone: (205) 934-7557 Fax: ...

The most common form of interstitial lung disease, idiopathic pulmonary fibrosis (IPF), has a life expectancy of approximately 3 to 5 years. But other, less severe types can have much longer ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterised by excessive fibrotic tissue deposition in the pulmonary parenchyma. The term "pulmonary" refers to the lungs ...

Hundreds of diseases that cause scarring or inflammation in your lungs are known as interstitial lung disease (ILD)—also called pulmonary fibrosis. All of these diseases make it more difficult to ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung tissue, which impairs oxygen exchange and leads to breathing difficulties.

MediawireNew Delhi [India], April 30: Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue deposition in the pulmonary parenchyma.

Almost 90% of Americans are unaware of the symptoms that signal pulmonary fibrosis due to the disease’s rarity, according to a Pulmonary Fibrosis Foundation survey. The foundation also noted ...

T abla maestro Zakir Hussain passed away on Monday, December 16, in a San Francisco hospital due to complications from a rare ...

PureTech Health plc (NASDAQ:PRTC) stock is up on Monday, after the company announced results from ELEVATE IPF Phase 2b trial of deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF).

Idiopathic pulmonary fibrosis is a progressive lung disorder characterised by lung scarring without any particular cause. According to StatPearls Publishing , the condition typically affects older ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.